Cargando…
Breakthrough cancer pain and rational drug use
Recent data indicate that there are large disparities in the use of opioid analgesics to control breakthrough cancer pain (BTcP) in Europe and worldwide. While it is clear that affordability is a key factor, it is certainly not the only one, and other factors, such as cultural differences and overal...
Autor principal: | Olarte, Juan Manuel Núñez |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357276/ https://www.ncbi.nlm.nih.gov/pubmed/28213817 http://dx.doi.org/10.1007/s00520-017-3636-5 |
Ejemplares similares
-
2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics
por: Sharp, Claire R., et al.
Publicado: (2022) -
Inflection Point: Ideas for Accelerating Breakthroughs and Improving Cardiovascular Health
por: Krumholz, Harlan M.
Publicado: (2020) -
Breakthrough cancer pain – still a challenge
por: Margarit, Cesar, et al.
Publicado: (2012) -
Rational Prescription for a Dermatologist
por: Prakash, Bhanu, et al.
Publicado: (2016) -
Management of breakthrough pain in children with cancer
por: Friedrichsdorf, Stefan J, et al.
Publicado: (2014)